A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations

European Journal of Pharmacology

Volumn 696, Issue 1-3, 2012, Pages 194-202

  Fukuda Tsuru, Sayaka ^a   Anabuki, Jun ^a   Abe, Yuji ^a   Yoshida, Kumiko ^a   Ishii, Shinichi ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Dipeptidyl peptidase 4; Dyslipidemia; Glucagon like peptide 1; Postprandial hyperglycemia; Teneligliptin; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; RECOMBINANT ENZYME; SITAGLIPTIN; TENELIGLIPTIN; TENELIGLIPTIN HYDROGEN BROMIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENCY; DYSLIPIDEMIA; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN; MALE; NITRILES; PYRAZINES; PYRAZOLES; PYRROLIDINES; RATS; RATS, WISTAR; RATS, ZUCKER; THIAZOLIDINES; TRIAZOLES;

EID: 84869093408     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.09.024     Document Type: Article

References (53)

1. B. Ahren, M. Landin-Olsson, P.A. Jansson, M. Svensson, D. Holmes, and A. Schweizer Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes J. Clin. Endocrinol. Metab. 89 2004 2078 2084 (Pubitemid 38619835)
2. D.J. Augeri, J.A. Robl, D.A. Betebenner, D.R. Magnin, A. Khanna, J.G. Robertson, A. Wang, L.M. Simpkins, P. Taunk, Q. Huang, S.P. Han, B. Abboa-Offei, M. Cap, L. Xin, L. Tao, E. Tozzo, G.E. Welzel, D.M. Egan, J. Marcinkeviciene, S.Y. Chang, S.A. Biller, M.S. Kirby, R.A. Parker, and L.G. Hamann Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 48 2005 5025 5037 (Pubitemid 41033142)
3. J.H. Bae, E. Bassenge, K.B. Kim, Y.N. Kim, K.S. Kim, H.J. Lee, K.C. Moon, M.S. Lee, K.Y. Park, and M. Schwemmer Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress Atherosclerosis 155 2001 517 523 (Pubitemid 32209324)
4. B. Balkan, L. Kwasnik, R. Miserendino, J.J. Holst, and X. Li Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats Diabetologia 42 1999 1324 1331 (Pubitemid 29500969)
5. G. Boden, and G.I. Shulman Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction Eur. J. Clin. Invest. 32 Suppl 3 2002 14 23 (Pubitemid 41704996)
6. B.F. Burkey, X. Li, L. Bolognese, B. Balkan, M. Mone, M. Russell, T.E. Hughes, and P.R. Wang Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats J. Pharmacol. Exp. Ther. 315 2005 688 695 (Pubitemid 41500734)
7. A. Ceriello, C. Taboga, L. Tonutti, L. Quagliaro, L. Piconi, B. Bais, R. Da Ros, and E. Motz Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment Circulation 106 2002 1211 1218 (Pubitemid 34988638)
8. C.F. Deacon Potential of liraglutide in the treatment of patients with type 2 diabetes Vasc. Health Risk Manage. 5 2009 199 211
9. C.F. Deacon, B. Ahren, and J.J. Holst Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin. Invest. Drugs 13 2004 1091 1102 (Pubitemid 39242733)
10. D.J. Drucker Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes Expert Opin. Invest. Drugs 12 2003 87 100 (Pubitemid 36104645)
11. M. Hanefeld, S. Fischer, U. Julius, J. Schulze, U. Schwanebeck, H. Schmechel, H.J. Ziegelasch, and J. Lindner Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up Diabetologia 39 1996 1577 1583 (Pubitemid 26397370)
12. J.J. Holst, and C.F. Deacon Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes Diabetes 47 1998 1663 1670 (Pubitemid 28476238)
13. J. Hsieh, C. Longuet, C.L. Baker, B. Qin, L.M. Federico, D.J. Drucker, and K. Adeli The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice Diabetologia 53 2010 552 561
14. T. Ikenoue, K. Okazaki, S. Fujitani, Y. Tsuchiya, M. Akiyoshi, T. Maki, and N. Kondo Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4- isopropylcyclohexanecarbonyl)-d-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide Biol. Pharm. Bull. 20 1997 354 359 (Pubitemid 27212992)
15. E. Ionescu, J.F. Sauter, and B. Jeanrenaud Abnormal oral glucose tolerance in genetically obese (fa/fa) rats The Am. J. Physiol. 248 1985 E500 506
16. K.G. Jackson, S.D. Poppitt, and A.M. Minihane Postprandial lipemia and cardiovascular disease risk: interrelationships between dietary, physiological and genetic determinants Atherosclerosis 220 2012 22 33
17. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, H. He, G.J. Hickey, J.E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M.E. McCann, R.A. Patel, A. Petrov, G. Scapin, S.B. Patel, R.S. Roy, J.K. Wu, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, and A.E. Weber (2R)-4-oxo-4-[3-(trifluoromethyl) -5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med. Chem. 48 2005 141 151 (Pubitemid 40105255)
18. B. Kreymann, G. Williams, M.A. Ghatei, and S.R. Bloom Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 2 1987 1300 1304 (Pubitemid 17156636)
19. A.M. Lambeir, C. Durinx, S. Scharpe, and I. De Meester Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit. Rev. Clin. Lab. Sci. 40 2003 209 294 (Pubitemid 36775376)
20. B. Lee, L. Shi, D.B. Kassel, T. Asakawa, K. Takeuchi, and R.J. Christopher Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys Eur. J. Pharmacol. 589 2008 306 314
21. R. Mahler, W.S. Stafford, M.E. Tarrant, and J. Ashmore The effect of insulin on lipolysis Diabetes 13 1964 297 302
22. J. Malone, M. Trautmann, K. Wilhelm, K. Taylor, and D.M. Kendall Exenatide once weekly for the treatment of type 2 diabetes Expert Opin. Invest. Drugs 18 2009 359 367
23. D. Marguet, L. Baggio, T. Kobayashi, A.M. Bernard, M. Pierres, P.F. Nielsen, U. Ribel, T. Watanabe, D.J. Drucker, and N. Wagtmann Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc. Nat. Acad. Sci. U.S.A. 97 2000 6874 6879 (Pubitemid 30412807)
24. N. Matikainen, S. Manttari, A. Schweizer, A. Ulvestad, D. Mills, B.E. Dunning, J.E. Foley, and M.R. Taskinen Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 49 2006 2049 2057 (Pubitemid 44168471)
25. Y. Moritoh, K. Takeuchi, T. Asakawa, O. Kataoka, and H. Odaka Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice Brit. J. Pharmacol. 157 2009 415 426
26. J. Mu, J. Woods, Y.P. Zhou, R.S. Roy, Z. Li, E. Zycband, Y. Feng, L. Zhu, C. Li, A.D. Howard, D.E. Moller, N.A. Thornberry, and B.B. Zhang Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes Diabetes 55 2006 1695 1704 (Pubitemid 44324122)
27. T. Nakagami Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin Diabetologia 47 2004 385 394 (Pubitemid 38491233)
28. D.M. Nathan Long-term complications of diabetes mellitus New Engl. J. Med. 328 1993 1676 1685 (Pubitemid 23157351)
29. B.G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women 298 2007 299 308 J. Am. Med. Assoc. 298 2007 299 308
30. N.D. Oakes, P.G. Thalen, S.M. Jacinto, and B. Ljung Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability Diabetes 50 2001 1158 1165 (Pubitemid 32374548)
31. R.A. Pederson, H.A. White, D. Schlenzig, R.P. Pauly, C.H. McIntosh, and H.U. Demuth Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide Diabetes 47 1998 1253 1258 (Pubitemid 28357002)
32. M. Pirro, P. Mauriege, A. Tchernof, B. Cantin, G.R. Dagenais, J.P. Despres, and B. Lamarche Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the quebec cardiovascular study Atherosclerosis 160 2002 377 384 (Pubitemid 34159331)
33. J. Pleiner, G. Schaller, F. Mittermayer, M. Bayerle-Eder, M. Roden, and M. Wolzt FFA-induced endothelial dysfunction can be corrected by vitamin C J. Clin. Endocrinol. Metab. 87 2002 2913 2917 (Pubitemid 34655363)
34. V. Poitout, and R.P. Robertson Glucolipotoxicity: fuel excess and beta-cell dysfunction Endocrine Rev. 29 2008 351 366 (Pubitemid 351679704)
35. J.A. Pospisilik, J. Martin, T. Doty, J.A. Ehses, N. Pamir, F.C. Lynn, S. Piteau, H.U. Demuth, C.H. McIntosh, and R.A. Pederson Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 52 2003 741 750 (Pubitemid 36323582)
36. R.E. Pratley, and A. Salsali Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes Curr. Med. Res. Opin. 23 2007 919 931 (Pubitemid 46631495)
37. X. Qin, H. Shen, M. Liu, Q. Yang, S. Zheng, M. Sabo, D.A. D'Alessio, and P. Tso GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am. J. Physiol. Gastrointest. liver Physiol. 288 2005 G943 949
38. H. Sakashita, F. Akahoshi, H. Kitajima, R. Tsutsumiuchi, and Y. Hayashi [(S)-gamma-(arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors Bioorg. Med. Chem. 14 2006 3662 3671
39. S. Singh, S. Roy, S. Sethi, B. Benjamin, S. Sundaram, V. Khanna, S.R. Kandalkar, C. Pal, R. Kant, A.K. Patra, G. Rayasam, S. Mittra, K.S. Saini, J. Paliwal, A. Chugh, S. Ahmed, J. Sattigeri, I. Cliff, A. Ray, V.S. Bansal, P.K. Bhatnagar, and J.A. Davis RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes Eur. J. Pharmacol. 652 2011 157 163
40. M.J. Stampfer, R.M. Krauss, J. Ma, P.J. Blanche, L.G. Holl, F.M. Sacks, and C.H. Hennekens A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction J. Am. Med. Assoc. 276 1996 882 888 (Pubitemid 26301607)
41. B. Sudre, P. Broqua, R.B. White, D. Ashworth, D.M. Evans, R. Haigh, J.L. Junien, and M.L. Aubert Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats Diabetes 51 2002 1461 1469 (Pubitemid 34826612)
42. K. Takasaki, M. Iwase, T. Nakajima, K. Ueno, Y. Nomoto, S. Nakanishi, and K. Higo K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent Eur. J. Pharmacol. 486 2004 335 342 (Pubitemid 38231064)
43. M.R. Taskinen Diabetic dyslipidaemia: from basic research to clinical practice Diabetologia 46 2003 733 749
44. The DECODE Study Group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European diabetes epidemiology group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe Lancet 354 1999 617 621
45. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl- quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors J. Pharmacol. Exp. Ther. 325 2008 175 182 (Pubitemid 351439162)
46. A.J. Tremblay, B. Lamarche, C.F. Deacon, S.J. Weisnagel, and P. Couture Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes Diabetes, Obes. Metab. 13 2011 366 373
47. R.H. Unger Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications Diabetes 44 1995 863 870
48. A. Vella, G. Bock, P.D. Giesler, D.B. Burton, D.B. Serra, M.L. Saylan, B.E. Dunning, J.E. Foley, R.A. Rizza, and M. Camilleri Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes Diabetes 56 2007 1475 1480 (Pubitemid 46715627)
49. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.F. Burkey, B.E. Dunning, K. Prasad, B.L. Mangold, M.E. Russell, and T.E. Hughes 1-[[(3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 46 2003 2774 2789 (Pubitemid 36702545)
50. M. Wojdemann, A. Wettergren, B. Sternby, J.J. Holst, S. Larsen, J.F. Rehfeld, and O. Olsen Inhibition of human gastric lipase secretion by glucagon-like peptide-1 Dig. Dis. Sci. 43 1998 799 805 (Pubitemid 28176470)
51. N. Yasuda, T. Nagakura, T. Inoue, K. Yamazaki, N. Katsutani, O. Takenaka, R. Clark, F. Matsuura, E. Emori, S. Yoshikawa, K. Kira, H. Ikuta, T. Okada, T. Saeki, O. Asano, and I. Tanaka E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3, 5-dihydro-4H-imidazo[4,5-d]pyridazin-4-o ne tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor Eur. J. Pharmacol. 548 2006 181 187 (Pubitemid 44397020)
52. T. Yoshida, F. Akahoshi, H. Sakashita, H. Kitajima, M. Nakamura, S. Sonda, M. Takeuchi, Y. Tanaka, N. Ueda, S. Sekiguchi, T. Ishige, K. Shima, M. Nabeno, Y. Abe, J. Anabuki, A. Soejima, K. Yoshida, Y. Takashina, S. Ishii, S. Kiuchi, S. Fukuda, R. Tsutsumiuchi, K. Kosaka, T. Murozono, Y. Nakamaru, H. Utsumi, N. Masutomi, H. Kishida, I. Miyaguchi, and Y. Hayashi Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H- pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-y lcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Bioorg. Med. Chem. 20 2012 5705 5719
53. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830 (Pubitemid 34233752)